Molecular biomarkers are a critical component in the treatment of adult and pediatric brain tumors. In this test-specific episode of the "Answers From the Lab" podcast, Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray provides more comprehensive and accurate tumor analysis compared with other test methods.

"The array test covers all the possibilities," Dr. Jenkins says. "It easily finds the various mutations that are essential for diagnosis and prognosis."

He notes that the chromosomal microarray is more accurate than fluorescence in situ hybridization (FISH), and requires less tumor content than methylation assay.

Each microarray is analyzed by an experienced Mayo Clinic pathologist. "We use our specialist knowledge about brain tumors and what we see in the microarray to generate a meaningful report that can guide a care plan for these complex brain tumors," Dr. Jenkins says.

Listen to learn more about Mayo Clinic Laboratories' chromosomal microarray assay.

Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

CMAPT | Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded

Useful information

• Genomic characterization of tumor for copy number imbalances and loss of heterozygosity.
• Assisting in the diagnosis and classification of malignant neoplasms.
• Evaluating the prognosis for patients with malignant tumors.

Specimen requirements

Specimen Required (submit only 1 of the following specimens):

• Specimen Type: Tissue
• Container/Tube: Formalin-fixed, paraffin-embedded tumor tissue block.

• Specimen Type: Slides
• Container/Tube: 10 Consecutive, unstained, 5-micron-thick sections placed on positively charged slides and 1 hematoxylin and eosin-stained slide.

Ordering Guidance: This test is not performed on fresh tissue specimens. If testing is needed for fresh tissue specimens, order CMAT / Chromosomal Microarray, Tumor, Fresh or Frozen using Affymetrix Cytoscan HD.

Necessary Information: A reason for testing and pathology report are required for testing to be performed. Send information with specimen. Acceptable pathology reports include working drafts, preliminary pathology or surgical pathology reports.

Performance information

Analytic time: 10 to 21 days

Days performed: Monday through Friday

The latest

Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D.

April 30, 2024

David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.

Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D.

April 23, 2024

Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.

Assay monitors response to monoclonal antibody therapy: Maria Alice Willrich, Ph.D.

April 16, 2024

Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.

View MoreView Less